We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > romosozumab

News List

Romosozumab Increases Bone Formation, Cuts Bone Resorption drugs
July 02, 2019
Romosozumab Increases Bone Formation, Cuts Bone Resorption.
EVENITY (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture firstwordpharma
January 09, 2019
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the Japanese Ministry of Health, Labor and Welfare has granted a marketing authorization for EVENITY™ (romosozumab) for the treatment of osteoporosis in patients at high risk of fr
UCB, Amgen refile osteoporosis drug Evenity pharmatimes
July 17, 2018
UCB and Amgen have brought their bone-boosting drug Evenity back to US regulators for review, following an initial rejection in July last year.
EMA accepts Marketing Authorization Application for romosozumab in the treatment of osteoporosis europeanpharmaceuticalreview
January 09, 2018
The EMA has accepted the Marketing Authorization Application for romosozumab in the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture…
Romosozumab provides protection against fractures in osteoporosis europeanpharmaceuticalreview
September 22, 2017
A new treatment for osteoporosis provides major improvements in bone density and fractures than the current standard treatment…